PET Radiomics Signatures and Artificial Intelligence for Decoding Immunotherapy Response in Advanced Cutaneous Squamous Cell Carcinoma: A Retrospective Single-Center Study
Guardado en:
| Udgivet i: | Applied Sciences vol. 15, no. 12 (2025), p. 6453-6471 |
|---|---|
| Hovedforfatter: | |
| Andre forfattere: | , , , , , , |
| Udgivet: |
MDPI AG
|
| Fag: | |
| Online adgang: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3223873146 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2076-3417 | ||
| 024 | 7 | |a 10.3390/app15126453 |2 doi | |
| 035 | |a 3223873146 | ||
| 045 | 2 | |b d20250615 |b d20250630 | |
| 084 | |a 231338 |2 nlm | ||
| 100 | 1 | |a Manco Luigi |u Medical Physics Unit, University Hospital of Ferrara, 44124 Ferrara, Italy; luigi.manco@ausl.fe.it (L.M.); scribanogiovanni@gmail.com (G.S.) | |
| 245 | 1 | |a PET Radiomics Signatures and Artificial Intelligence for Decoding Immunotherapy Response in Advanced Cutaneous Squamous Cell Carcinoma: A Retrospective Single-Center Study | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Radiomic analysis of baseline [18F]FDG PET/CT scans may offer a non-invasive tool to predict immunotherapy response and tumor grade in patients with advanced cutaneous squamous cell carcinoma. This approach could support clinical decision making by identifying likely responders prior to treatment initiation and tailoring management strategies based on tumor differentiation. The aim of this study was to develop a baseline [18F]FDG PET/CT model to predict immunotherapy response in advanced cutaneous squamous cell carcinoma (cSCC) and noninvasively determine tumor grade, thereby enhancing early patient stratification. We retrospectively analyzed 59 patients with histologically confirmed advanced cSCC submitted to immunotherapy with cemiplimab. All underwent [18F]FDG PET/CT at baseline and after approximately 12 weeks. Clinical response was assessed through PET findings integrated with clinical and dermatological evaluation, and patients were classified as responders (complete/partial metabolic response or stable disease) or non-responders (progression or toxicity-related discontinuation). Tumors were also classified as low to intermediate (G1–G2) or poorly differentiated (G3). Machine learning models (Random Forest and Extreme Gradient Boosting) were trained to predict treatment response and tumor grade. Clinical benefit was observed in 46/59 patients (77.9%), while 13 (22.1%) were non-responders. Histology showed 64.4% (n = 38) G1–G2 and 35.6% (n = 21) G3 tumors. The PET-based model best predicted clinical benefit (AUC = 0.96, accuracy = 91% cross-validation; AUC = 0.88, accuracy = 82% internal validation). For tumor grade prediction, the CT-based model achieved a higher AUC of 0.80 (accuracy 73%), whereas the PET-based model reached an AUC of 0.78 but demonstrated a slightly higher accuracy of 77%. Radiomic analysis of baseline [18F]FDG PET enables the discriminative prediction of immunotherapy response and tumor grade in advanced cSCC, with PET-based models outperforming CT-based ones. | |
| 610 | 4 | |a GE Healthcare | |
| 653 | |a Radiomics | ||
| 653 | |a Patients | ||
| 653 | |a Work stations | ||
| 653 | |a Machine learning | ||
| 653 | |a Metastasis | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Artificial intelligence | ||
| 653 | |a Immunotherapy | ||
| 653 | |a Metabolic disorders | ||
| 653 | |a Skin cancer | ||
| 653 | |a Response rates | ||
| 653 | |a Biomarkers | ||
| 653 | |a Squamous cell carcinoma | ||
| 653 | |a Tumors | ||
| 653 | |a Medical imaging | ||
| 653 | |a Nuclear medicine | ||
| 653 | |a Drug dosages | ||
| 700 | 1 | |a Proietti Ilaria |u Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; ilaria.proietti@uniroma1.it (I.P.); concetta.potenza@uniroma1.it (C.P.) | |
| 700 | 1 | |a Scribano Giovanni |u Medical Physics Unit, University Hospital of Ferrara, 44124 Ferrara, Italy; luigi.manco@ausl.fe.it (L.M.); scribanogiovanni@gmail.com (G.S.) | |
| 700 | 1 | |a Pirisino Riccardo |u Department of Nuclear Medicine, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy; r.pirisino@ausl.latina.it (R.P.); o.bagni@ausl.latina.it (O.B.) | |
| 700 | 1 | |a Bagni Oreste |u Department of Nuclear Medicine, Santa Maria Goretti Hospital, AUSL Latina, 04100 Latina, Italy; r.pirisino@ausl.latina.it (R.P.); o.bagni@ausl.latina.it (O.B.) | |
| 700 | 1 | |a Potenza Concetta |u Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; ilaria.proietti@uniroma1.it (I.P.); concetta.potenza@uniroma1.it (C.P.) | |
| 700 | 1 | |a Pellacani Giovanni |u Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Dermatology Clinic, Sapienza University, 00184 Rome, Italy; giovanni.pellacani@uniroma1.it | |
| 700 | 1 | |a Filippi Luca |u Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy | |
| 773 | 0 | |t Applied Sciences |g vol. 15, no. 12 (2025), p. 6453-6471 | |
| 786 | 0 | |d ProQuest |t Publicly Available Content Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3223873146/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3223873146/fulltextwithgraphics/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3223873146/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |